chlorambucil has been researched along with Myelodysplastic Syndromes in 19 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We recently observed a 39-year-old female patient with Behçet's disease developing a myelodysplastic syndrome (MDS) FAB subtype refractory anemia with excess of blasts in transformation [RAEB-t] with a monosomy 7 after being treated with cyclosporin A and chlorambucil for several years." | 3.70 | Myelodysplastic syndrome with monosomy 7 after immunosuppressive therapy in Behçet's disease. ( Bangerter, M; Griesshammer, M; Hafner, M; Heil, G; Heiss, M; Kern, P; Kern, W; Krauter, J; v Tirpitz, C, 1999) |
| " Although multi-drug therapy is known to produce myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in patients with CTD, treatment with single-agent therapy, particularly methotrexate, has rarely been associated with secondary MDS or AML." | 3.69 | Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. ( Farhi, DC; Rosenthal, NS, 1996) |
| "Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual." | 2.70 | Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. ( Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L, 2002) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "To date, the majority of trials on chronic lymphocytic leukemia (CLL) focused on patients considerably younger than the median age of onset for CLL." | 1.39 | First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. ( Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L, 2013) |
| "Cytogenetic analysis showed complex chromosomal abnormalities including 5q deletion, 12p deletion and monosomy 18." | 1.33 | Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine. ( Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ, 2005) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| da Cunha-Bang, C | 1 |
| Rostgaard, K | 1 |
| Andersen, MA | 1 |
| Rotbain, EC | 1 |
| Grønbaek, K | 1 |
| Frederiksen, H | 1 |
| Niemann, CU | 1 |
| Hjalgrim, H | 1 |
| Michallet, AS | 1 |
| Cazin, B | 1 |
| Bouvet, E | 1 |
| Oberic, L | 1 |
| Schlaifer, D | 1 |
| Mosser, L | 1 |
| Salles, G | 1 |
| Coiffier, B | 1 |
| Laurent, G | 1 |
| Ysebaert, L | 1 |
| Leleu, X | 1 |
| Soumerai, J | 1 |
| Roccaro, A | 1 |
| Hatjiharissi, E | 1 |
| Hunter, ZR | 1 |
| Manning, R | 1 |
| Ciccarelli, BT | 1 |
| Sacco, A | 1 |
| Ioakimidis, L | 1 |
| Adamia, S | 1 |
| Moreau, AS | 1 |
| Patterson, CJ | 1 |
| Ghobrial, IM | 1 |
| Treon, SP | 1 |
| Bauer, K | 1 |
| Herbst, C | 1 |
| Brillant, C | 1 |
| Monsef, I | 1 |
| Kluge, S | 1 |
| Skoetz, N | 1 |
| Engert, A | 1 |
| Morrison, VA | 1 |
| Rai, KR | 1 |
| Peterson, BL | 1 |
| Kolitz, JE | 1 |
| Elias, L | 1 |
| Appelbaum, FR | 1 |
| Hines, JD | 1 |
| Shepherd, L | 1 |
| Larson, RA | 1 |
| Schiffer, CA | 1 |
| Metayer, C | 1 |
| Curtis, RE | 1 |
| Vose, J | 1 |
| Sobocinski, KA | 1 |
| Horowitz, MM | 1 |
| Bhatia, S | 1 |
| Fay, JW | 1 |
| Freytes, CO | 1 |
| Goldstein, SC | 1 |
| Herzig, RH | 1 |
| Keating, A | 1 |
| Miller, CB | 1 |
| Nevill, TJ | 1 |
| Pecora, AL | 1 |
| Rizzo, JD | 1 |
| Williams, SF | 1 |
| Li, CY | 1 |
| Travis, LB | 1 |
| Weisdorf, DJ | 1 |
| Fruchtman, SM | 1 |
| Yen, CJ | 1 |
| Huang, WT | 1 |
| Huang, JJ | 1 |
| Chen, FF | 1 |
| Sung, JM | 1 |
| Balakrishnan, C | 1 |
| Pathan, E | 1 |
| Khodaiji, S | 1 |
| Dasgupta, A | 1 |
| Mangat, G | 1 |
| Joshi, VR | 1 |
| Shin, SJ | 1 |
| Chun, SH | 1 |
| Kim, KO | 1 |
| Kim, MK | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Cho, HS | 1 |
| Bauer, A | 1 |
| Garbe, C | 1 |
| Detmar, M | 1 |
| Kreuser, ED | 1 |
| Gollnick, H | 1 |
| Rosenthal, NS | 1 |
| Farhi, DC | 1 |
| Shammas, FV | 1 |
| Heikkilä, R | 1 |
| McCarthy, CJ | 1 |
| Sheldon, S | 1 |
| Ross, CW | 1 |
| McCune, WJ | 1 |
| Bangerter, M | 1 |
| Griesshammer, M | 1 |
| v Tirpitz, C | 1 |
| Krauter, J | 1 |
| Heil, G | 1 |
| Hafner, M | 1 |
| Kern, W | 1 |
| Heiss, M | 1 |
| Kern, P | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 1 |
| Sirianni, MC | 1 |
| Barbone, B | 1 |
| Monarca, B | 1 |
| Nanni, M | 1 |
| Laganà, B | 1 |
| Aiuti, F | 1 |
| Mahoney, DH | 1 |
| McClain, KL | 1 |
| Hanson, IC | 1 |
| Taylor, LD | 1 |
| Steuber, CP | 1 |
| Bennett, JM | 1 |
| Moloney, WC | 1 |
| Greene, MH | 1 |
| Boice, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)[NCT04125290] | 2 participants (Actual) | Observational | 2019-12-09 | Terminated (stopped due to Study stopped due to lack of recruitment.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for chlorambucil and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
[Multicentric reticulohistiocytosis and myelodysplastic syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Diagnosis, Differential; | 1994 |
1 trial available for chlorambucil and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambuci | 2002 |
16 other studies available for chlorambucil and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chloramb | 2021 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlora | 2013 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; F | 2009 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Ble | 2010 |
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2003 |
Prolonged chlorambucil therapy for idiopathic membranous nephropathy may induce myelodysplastic syndrome and acute leukemia: report of a case.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Chlorambucil; Chromosomes, Human, Pair 7; F | 2004 |
Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
Topics: Acute Disease; Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Chlorambucil; Fatal Outcome | 2004 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2005 |
Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy.
Topics: Acute Disease; Adult; Aged; Antigens, CD; Antirheumatic Agents; Chlorambucil; Connective Tissue Dise | 1996 |
[Secondary myelodysplastic syndrome].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Chlorambucil; Cyclophos | 1997 |
Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Chromosome Aberrations; Chromosome Disorders; Chromoso | 1998 |
Myelodysplastic syndrome with monosomy 7 after immunosuppressive therapy in Behçet's disease.
Topics: Adult; Antineoplastic Agents, Alkylating; Behcet Syndrome; Bone Marrow Cells; Chlorambucil; Chromoso | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
A case of Behćet's disease complicated by visceral Leishmaniasis and myelodysplasia: clinical considerations.
Topics: Adult; Antineoplastic Agents, Alkylating; Autoimmune Diseases; Behcet Syndrome; Chlorambucil; Humans | 2001 |
Acquired immune deficiency, myelodysplasia, and acute nonlymphocytic leukemia associated with monosomy 7 and t(3;3) (q21;q26) in a child with Langerhans cell histiocytosis.
Topics: Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Female; H | 1989 |
Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Anemia, Aplastic; Child; Child, Preschool; Chlorambucil; | 1987 |